Status: Recruiting
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma
The P-EVOLUTION trial is a prospective, multicenter, non-interventional observational study aimed at investigating peripheral neuropathy in patients receiving first-line treatment for metastatic or locally advanced urothelial carcinoma with enfortumab vedotin (EV) and pembrolizumab (P). Conducted at two German university hospitals, the study will track the incidence and severity of peripheral neuropathy, its impact on quality of life, and treatment regimen adjustments due to side effects. Approximately 80 patients are expected to be enrolled over one year.
Participants needed: 80
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Comprehensive Cancer Center Munich (CCCM)Updated: Feb 24, 2026Locations: 4
Eligibility criteria
Adult patients, ≥18 years of age at the time of signing the informed consent for... [+3]
Patients with contraindications for enfortumab vedotin and/or pembrolizumab [+3]